The Medicines and Healthcare products Regulatory Agency (MHRA) have provided details of legislation to ensure continuity of supply of medicines, medical devices and clinical trials in a no deal Brexit.
Leaving the EU with a deal remains the Government’s top priority. This has not changed. However, a responsible government must plan for every eventuality, including a no deal scenario.
Contingency legislation is needed in order for the Medicines and Healthcare products Regulatory Agency to be able to take on regulatory processes for human medicines and devices that are currently undertaken by the European Medicines Agency and other bodies in the event of no deal being agreed with the EU.
In the event of the UK leaving the EU without a deal, the Government is putting in place legislation to allow the continued sale of, and access to, medicines, medical devices and clinical trials. This will be done via three separate pieces of legislation:
1. Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc) (EU Exit) Regulations 2019
2. The Medical Devices (amendment) (EU exit) Regulations 2019
3. The Medicines for Human Use (Clinical Trials) (amendment) (EU exit) Regulations 2019
These Regulations are subject to approval by Parliament and were laid in Parliament this week.
These Regulations set out a comprehensive regime for the authorisation of medicinal products for human use; for the manufacture, import, distribution, sale and supply of those products; for their labelling and advertising; and for pharmacovigilance. They also provide for enforcement powers for the authorisation and supervision of medicinal products for human use.
The 2012 Regulations (as amended by the 2019 Regulations) make reference to various pieces of EU guidance, as that stood immediately before exit day. These can be accessed at GOV.UK
The Medicines and Healthcare products Regulatory Agency (MHRA) is the designated competent authority that administers and enforces the law on medical devices in the UK. It has a range of investigatory and enforcement powers to ensure their safety and quality. These regulations ensure that the required powers are provided for.
The Clinical Trial Regulations require all interventional clinical trials of medicines to be authorised by the MHRA, as the national competent authority in the UK; to have a favourable ethics opinion; and to be conducted according to Good Clinical Practice. They also include requirements for the assessment and supply of investigational medicinal products and for safety reporting.